[SCHEDULE 13G/A] Stoke Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Redmile Group, LLC and Jeremy C. Green report shared beneficial ownership of 4,375,931 shares of Stoke Therapeutics common stock, representing 8.0% of the outstanding class based on 54,596,924 shares. The position is held through Redmile-managed investment vehicles, including Redmile Biopharma Investments III, L.P., which directly holds 3,505,612 shares (6.4%). The filers report shared voting and dispositive power over these shares and disclaim sole ownership, indicating the stake is held on behalf of Redmile clients rather than directly by the reporting individuals or manager.

Positive

• Material disclosure of stake: 4,375,931 shares representing 8.0% of class is clearly reported
• Specific fund attribution: Redmile Biopharma Investments III, L.P. holds 3,505,612 shares (6.4%)
• Clear governance disclosures: Shared voting and dispositive power and customary disclaimers are included

Negative

• No sole voting or dispositive power: Reporting persons do not report exclusive control over the shares
• Ownership held through client vehicles: Beneficial ownership is via Redmile-managed funds, not direct individual holdings

Insights

Financial Analyst

TL;DR: Redmile discloses a material 8.0% shared stake in STOK via managed funds, representing a sizable institutional position.

Redmile Group, LLC and Jeremy C. Green report shared beneficial ownership of 4,375,931 shares, equal to 8.0% of Stoke Therapeutics' common stock based on 54,596,924 shares outstanding. A named fund, Redmile Biopharma Investments III, L.P., holds 3,505,612 shares (6.4%). The filing shows shared voting and dispositive power only, which means control resides with the investment vehicles and not a single holder. For investors, this filing clarifies ownership concentration and potential investor composition without indicating any change in control intent.

Corporate Governance Expert

TL;DR: Governance disclosure shows an institutional manager and principal with shared authority over an 8.0% position, properly disclaiming sole ownership.

The Schedule 13G/A identifies Redmile Group, LLC as investment manager and Jeremy C. Green as principal, each disclaiming direct ownership except to the extent of pecuniary interest. Shared voting and dispositive powers are reported, and one fund, RBI III, is disclosed as holding 3,505,612 shares. The filing provides clear attribution of beneficial ownership and appropriate disclaimers consistent with passive reporting obligations under Schedule 13G.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

Stoke Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

86150R107

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 86150R107

1

Names of Reporting Persons

Redmile Group, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,375,931.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,375,931.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,375,931.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.0 %

12

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person: Redmile Group, LLC's beneficial ownership of the Issuer's common shares ("Common Stock") is comprised of 4,375,931 shares of Common Stock owned by certain private investment vehicles managed by Redmile Group, LLC (collectively, the "Redmile Clients"), including Redmile Biopharma Investments III, L.P. ("RBI III"). The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of such Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Percentage based on 54,596,924 shares of Common Stock outstanding as of April 30, 2025, as reported by the Issuer in its Form 10-Q for the quarterly period ended March 31, 2025 filed with the Securities and Exchange Commission on May 13, 2025 (the "Form 10-Q").

SCHEDULE 13G

CUSIP No. 86150R107

1

Names of Reporting Persons

Jeremy C. Green

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 4,375,931.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 4,375,931.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,375,931.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

8.0 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Jeremy C. Green's beneficial ownership of the Common Stock is comprised of 4,375,931 shares of Common Stock owned by certain Redmile Clients, including RBI III. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of such Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. Percentage based on 54,596,924 shares of Common Stock outstanding as of April 30, 2025, as reported by the Issuer in the Form 10-Q.

SCHEDULE 13G

CUSIP No. 86150R107

1

Names of Reporting Persons

Redmile Biopharma Investments III, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,505,612.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,505,612.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,505,612.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.4 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Percentage based on 54,596,924 shares of Common Stock outstanding as of April 30, 2025, as reported by the Issuer in the Form 10-Q.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Stoke Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 45 Wiggins Ave, Bedford, MA, 01730
Item 2.
(a)	Name of person filing: Redmile Group, LLC Jeremy C. Green Redmile Biopharma Investments III, L.P.
(b)	Address or principal business office or, if none, residence: Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129 Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001 Redmile Biopharma Investments III, L.P. c/o Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129
(c)	Citizenship: Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom Redmile Biopharma Investments III, L.P.: Delaware
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP No.: 86150R107
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Redmile Group, LLC - 4,375,931 (1) Jeremy C. Green - 4,375,931 (1) Redmile Biopharma Investments III, L.P. - 3,505,612
(b)	Percent of class: Redmile Group, LLC - 8.0% (2) Jeremy C. Green - 8.0% (2) Redmile Biopharma Investments III, L.P. - 6.4% (2)
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments III, L.P. - 0
	(ii) Shared power to vote or to direct the vote: Redmile Group, LLC - 4,375,931 (1) Jeremy C. Green - 4,375,931 (1) Redmile Biopharma Investments III, L.P. - 3,505,612
	(iii) Sole power to dispose or to direct the disposition of: Redmile Group, LLC - 0 Jeremy C. Green - 0 Redmile Biopharma Investments III, L.P. - 0
	(iv) Shared power to dispose or to direct the disposition of: Redmile Group, LLC - 4,375,931 (1) Jeremy C. Green - 4,375,931 (1) Redmile Biopharma Investments III, L.P. - 3,505,612 (1) Redmile Group, LLC's and Jeremy C. Green's beneficial ownership of the Issuer's Common Stock is comprised of 4,375,931 shares of Common Stock owned by the Redmile Clients, including RBI III. The reported securities may be deemed beneficially owned by Redmile Group, LLC as investment manager of the Redmile Clients. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile Group, LLC. Redmile Group, LLC and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any. (2) Percentage based on 54,596,924 shares of Common Stock outstanding as of April 30, 2025, as reported by the Issuer in the Form 10-Q.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See the response to Item 4.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Redmile Group, LLC

Signature:	/s/ Jeremy C. Green
Name/Title:	Managing Member
Date:	08/14/2025

Jeremy C. Green

Signature:	/s/ Jeremy C. Green
Name/Title:	Jeremy C. Green
Date:	08/14/2025

Redmile Biopharma Investments III, L.P.

Signature:	/s/ Jeremy C. Green
Name/Title:	Managing Member of Redmile Biopharma Investments III (GP), LLC, general partner of Redmile Biopharma Investments III, L.P.
Date:	08/14/2025

FAQ

How many Stoke Therapeutics (STOK) shares does Redmile Group report owning?

Redmile Group, LLC reports beneficial ownership of 4,375,931 shares of common stock, representing 8.0% of the class.

What stake does Redmile Biopharma Investments III, L.P. hold in STOK?

Redmile Biopharma Investments III, L.P. holds 3,505,612 shares, equal to 6.4% of the outstanding common stock.

Do the reporting persons have sole voting or dispositive power over the shares?

No. The filing reports 0 shares with sole voting or dispositive power and 4,375,931 shares with shared voting and dispositive power.

On what outstanding share base are the percentages calculated?

Percentages are based on 54,596,924 shares of common stock outstanding as reported by the issuer as of April 30, 2025.

Does the filing indicate the stake is held for the reporting persons personally?

No. The filing states the shares are owned by Redmile-managed clients and includes disclaimers that Redmile Group, LLC and Jeremy C. Green disclaim beneficial ownership except to any pecuniary interest.